ARHGEF7 and adenocarcinoma: Arhgef7 CKO mice had 39% fewer colon tumors (3.25 ± 0.47 tumors/control versus 2.00 ± 0.37 tumors/CKO mouse) (Fig. 6c) − 55% fewer adenocarcinomas and 24% fewer adenomas (both p = 0.04; Fig. 6d).